Brought to you by 
Portola Pharmaceuticals raises $46mm in Series B
19 Apr 2021
Executive Summary
Portola Pharmaceuticals (developing antithrombotics) raised $46mm in its second venture financing. The company was set up two years ago by former executives of Cor Therapeutics who brought with them key platelet biology programs licensed from Cor's acquirer, Millennium Pharmaceuticals.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Portola Pharmaceuticals raises $46mm in Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice